One in 10 elderly people taking drugs for chronic conditions spent more than 10% of their income on medication, and the probability of having an expenditure burden among elderly persons was 3.8 times as high as that among the nonelderly. The low-income status of elderly Koreans, combined ...
(WC, HDL-C, TGs, SBP) and glycemic control (decrease in HbA1c by 0.2–0.7%) in overweight or obese patients with or without T2D [210,211]. The RIO (Rimonabant In Obesity) Europe study, in which obese adults with or without comorbidities were assigned to placebo (n = 305), ...
he use of anti-psychotics is higher in older people than their younger adult counterparts due to high prevalence of dementia/delirium. Anti-psychotic drugs cause side effects which include cardiovascular, metabolic, extra pyramidal and risk of falls. So, we set out to do a QIP on antipsychotic...
Objective The rational medication route of puerarin was explore d by studying the concentration- time curve and by comparing the histological and organic distribution difference of puerarin administered by intravenous injecti on or gastric gavage in mice, so as to supply a referential data for its ra...
Patients with hypertension were eligible if 1) the diagnosis of arterial hypertension was documented in their medical records, and 2) the patient was being prescribed at least one medication for high blood pressure regardless of whether hypertension was controlled (< 140 mmHg systolic and < 90 ...
If you have side effects from diabetes medications, or if your medicine interacts with other drugs, it might be time for a change. Find out what your options are.
TRIJARDY XR can help lower your A1C TRIJARDY XR contains the benefits of 3 medications: Type 2 diabetes can make it hard to control your A1C—it may be time for a medication that works in multiple ways. TRIJARDY XR combines 3 diabetes medications—JARDIANCE (empagliflozin), TRADJENTA (...
dietary, pharmaceutical, and behavior treatments for obesity are associated with high failure rates, and medical management of diabetes is also often unsuccessful. despite many efforts to improve the control of glucose levels in diabetes, including clinical guidelines and patient and provider education, ...
Phosphodiesterase type 5 (PDE5) inhibitor drugs for erectile dysfunction have revolutionised the treatment of male sexual dysfunction and are among the bes... HV Danesh-Meyer,LA Levin - 《British Journal of Ophthalmology》 被引量: 41发表: 2007年 Association between falls and high‐risk medication...
Moreover, in June 2023, Eli Lilly's phase 2 trial results for orforglipron demonstrated significant weight reduction and A1C improvements in adults with obesity or overweight and type 2 diabetes, marking another significant advancement in the field. If confirmed in phase 3 trials, these findings...